This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

DaVita Clinical Research Announces Scientific Collaboration With Dr. Jon Ruckle

Stocks in this article: DVA

DaVita Clinical Research ® (DCR ®), a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today a non-exclusive agreement with Pacific Pharma Group, LLC, to provide consulting, program strategy and protocol design support for clinical pharmacology studies performed at DCR.

Jon Ruckle, M.D., CPI, principal at Pacific Pharma Group, will collaborate with DCR to continue to expand DCR’s Phase I research capabilities. Dr. Ruckle has served as investigator for more than 350 studies across multiple therapeutic areas including diabetes, cardiovascular disease, hypertension and osteoporosis, as well as first-in-human trials with biologics and small molecules.

“We are excited to enter into this consulting relationship with Pacific Pharma Group and to extend our scientific team to include the experience of Dr. Ruckle,” said Chad Jaeger, vice president of early clinical research at DCR. “Our intense focus on patient safety and scientific integrity in complex clinical pharmacology services aligns well with this collaboration and the needs of our customers.”

In addition to serving as principal at Pacific Pharma Group, Dr. Ruckle is currently assistant clinical professor at the John A. Burns School of Medicine at the University of Hawaii in Honolulu. Previously, he held medical director positions at Comprehensive Clinical Development, Inc., Covance Clinical Research Unit and Radiant Research Unit Honolulu. He was medical director and co-founder of Northwest Kinetics, Inc., and has authored more than 30 medical publications.

“State-of-the-art, hospital-based Phase I facilities offering access to both patient and healthy normal populations are of great interest to pharmaceutical researchers,” said Dr. Ruckle. “Through our relationship with DCR, Pacific Pharma Group will be able to offer clients access to these valuable services.”

Dr. Ruckle completed his medical degree at the Loma Linda University Medical School in Loma Linda, Calif., and his internal medicine residency training at the Mayo Clinic in Rochester, Minn. Dr. Ruckle is board certified in Internal Medicine and is a Certified Physician Investigator through the Academy of Pharmaceutical Physicians and Investigators.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,612.94 +256.07 1.48%
S&P 500 2,039.88 +26.99 1.34%
NASDAQ 4,706.6420 +62.33 1.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs